Targa Therapeutic Pipeline

TARGA PROPRIETARY DRUG CANDIDATES

Using its Therapeutic Payload technologies, Targa is developing its own proprietary drug candidates and as well as helping other companies to increase the therapeutic windows of their targeting moieties. Targa is interested in finding developmental partners for its proprietary drug candidate programs. Targa’s most advanced proprietary products are:

Targa Pipeline Summary

Compound Name	Compound Type	Indications	Development Stage
VEGF/rGel	Growth Factor-payload fusion protein vascular disruptive agent	Multiple Solid Tumors Macular Degeneration Diabetic Retinopathy	Advanced Pre-Clinical

Granzyme B/VEGF	Growth Factor-payload fusion protein vascular disruptive agent	Multiple Solid Tumors Macular Degeneration Diabetic Retinopathy	Pre-Clinical

BreMel/rGel (scFvMel/rGel)	MAb scFv fragment-payload fusion protein	Melanoma Lobular Breast Cancer	Advanced Pre-Clinical

BreMel/TNF-a (scFvMel/TNF-a)	MAb scFv fragment-payload fusion protein	Melanoma Lobular Breast Cancer	Pre-Clinical

HuM195/rGel	Antibody-payload chemical conjugate	AML, CML Myelodysplastic Syndrome	Phase I ongoing (2 studies)

scFv23/rGel	MAb scFv fragment-payload fusion protein	HER2+ Breast Cancer	Pre-Clinical

PRODUCT CANDIDATES : Product Candidates | Clinical Trial Locations

HOME - TECHNOLOGIES - PRODUCT CANDIDATES - SERVICES - ABOUT US - CONTACT